TernaryTx news.
TernaryTx raises €4.1 million in seed funding
Daphni leads the €4.1 million round, co-invested by Pace Ventures, i&i Biotech Fund and UK Innovation & Science Seed Fund (managed by Future Planet Capital).
This investment enables us to scale our AI-driven platform to discover molecular glue therapeutics. By combining physics-informed AI with rapid experimental validation, TernaryTx is turning what has historically been a chance discovery process into a repeatable engineering system for drug discovery.
As part of its next phase, Dr Ian Taylor was appointed to the Board. Dr Taylor is a veteran of targeted protein degradation research and was recently CSO and President of R&D at Arvinas.
Preprint: benchmarking FEP against Boltz-2 for binding affinity prediction
This study presents the first comprehensive comparison of two computational methods for predicting binding affinity: the accurate-but-costly Free Energy Perturbation (FEP) and the fast co-folding model Boltz-2. Across 140 measurements on six complexes, FEP consistently demonstrated strong predictive accuracy. The paper also shows the ability of FEP to predict selectivity between off-targets.
Read preprint →TernaryTx comes out of stealth
Platform announced: Leopard, Puffin, Gecko, and Octopus — four interconnected tools combining AI and molecular dynamics for the rational design of molecular glue therapeutics targeting undruggable proteins.